Lv7
5000 积分 2024-09-13 加入
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
19天前
已完结
The utility of intravenous immunoglobulin infection prophylaxis in patients on anti-CD38 therapies
2个月前
已完结
Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma
3个月前
已完结
Comparative efficacy of anti‐CD38 monoclonal antibodies in multiple myeloma using a network meta‐analysis
4个月前
已完结
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
4个月前
已完结
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
4个月前
已关闭
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
4个月前
已完结
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
4个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
4个月前
已完结
Perspectives on Newly Diagnosed Myeloma Treatment and Emerging Challenges
4个月前
已完结
皖公网安备34019202002308
